NCT00910429 - BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension | Biotech Hunter

Enrollment

237

Participants

Timeline

Start Date

July 1, 2009

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions

Pulmonary Hypertension

Interventions

DRUG

Riociguat (Adempas, BAY63-2521)

BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study

Trial Locations (73)

100

Taipei

1070

Bruxelles - Brussel

1090

Vienna

3000

Leuven

3181

Prahran

3400

Corrientes

8091

Zurich

8200

Aarhus N

12808

Prague

14080

Mexico City

20251

Hamburg

21205

Baltimore

27100

Pavia

30625

Hanover

34093

Istanbul

35040

Izmir

35392

Giessen

38000

Querétaro

43221

Columbus

44195

Cleveland

50924

Cologne

52242

Iowa City

54511

Vandœuvre-lès-Nancy

64718

Monterrey

66421

Homburg

69126

Heidelberg

75390

Dallas

76031

Rouen

81377

München

92093

La Jolla

94275

Le Kremlin-Bicêtre

95817

Sacramento

97074

Würzburg

100020

Beijing

100037

Beijing

197341

Saint Petersburg

200433

Shanghai

630055

Novosibirsk

02118

Boston

90020 090

Porto Alegre

04020-050

São Paulo

21941-913

Rio de Janeiro

T1Y 6J4

Calgary

N6A 4G5

London

K1Y 4W7

Ottawa

M5G 2N2

Toronto

H3T 1E2

Montreal

F-29609

Brest

01307

Dresden

04103

Leipzig

Unknown

Rabin Medical Center - Beilinson Campus, Petah Tikva

Ankara

467-8602

Nagoya

802-8555

Kitakyushu

923-8560

Komatsu

251-0041

Fujisawa

216-8511

Kawasaki

980-8574

Sendai

392-8510

Suwa

113-8655

Bunkyo-ku

162-8655

Shinjuku-ku

260-8677

Chiba

812-8582

Fukuoka

31-202

Krakow

05-400

Otwock

3000-075

Coimbra

1649-035

Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisbon

833 48

Bratislava

06351

Seoul

138-736

Seoul

08036

Barcelona

CB23 3RE

Cambridge

G81 4DY

Glasgow